Stockscreener 앱 받기
5.56
3.93%
0.21
시간 외 거래:
5.60
0.04
+0.72%
Replimune Group Inc 주식(REPL)의 최신 뉴스
Is Replimune Group Inc. stock reversal real or fakeCPI Data & Advanced Technical Analysis Signals - Newser
REPL Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. (REPL)Contact Kessler Topaz Meltzer & Check, LLP - FinancialContent
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Replimune - GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPL - GlobeNewswire Inc.
Bragar Eagel & Squire, P.C. Reminds Investors of Class - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming DeadlinesREPL - PR Newswire
ROSEN, THE FIRST FILING FIRM, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by The FirmREPL - ACCESS Newswire
Lawsuit filed for Investors who lost money with shares of Replimune Group, Inc. (NASDAQ: REPL) - openPR.com
Replimune (REPL) Faces Securities Class Action Following - GlobeNewswire
Shareholders of Replimune Group, Inc. (REPL): Protect Your Rights Before September 22, 2025Contact Levi & Korsinsky - ACCESS Newswire
Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025REPL - MarketScreener
Class Action Announcement for Replimune Group, Inc. (REPL): Kessler Topaz Meltzer & Check, LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. - MarketScreener
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. LawsuitREPL - WV News
Replimune Group Stock Soars 17.76% Amid FDA Rejection Lawsuit - AInvest
Momentum divergence signals in Replimune Group Inc. chart2025 Biggest Moves & Safe Swing Trade Setups - Newser
Replimune Group’s SWOT analysis: oncology biotech stock faces FDA hurdles - Investing.com
Replimune Group, Inc. shares rise 11.59% after-hours following securities class action lawsuits. - AInvest
REPL LAWSUIT ALERT: Levi & Korsinsky Notifies Replimune Group, Inc. Investors of a Class - Bluefield Daily Telegraph
REPL LAWSUIT ALERT: Levi & Korsinsky Notifies Replimune - GlobeNewswire
REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm - cnhinews.com
Class Action Announcement for Replimune Group, Inc. (REPL): - GlobeNewswire
REPL LAWSUIT ALERT: The Gross Law Firm Notifies Replimune Group, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - Morningstar
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
Shareholders who lost money on Replimune Group, Inc. - GlobeNewswire
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Did You Lose Money on Replimune Group, Inc. (REPL)? Levi & Korsinsky Urges Investors to Act Before September 22, 2025 - ACCESS Newswire
REPL Stock News: Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Replimune Group, Inc. Class Action Lawsuit - The Malaysian Reserve
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - GlobeNewswire
Replimune Group, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationREPL - PR Newswire
Replimune (REPL) Faces Securities Class Action Following Stock’s Collapse Amid FDA’s Rejection of Melanoma Drug - GlobeNewswire Inc.
Investor Alert: Deadline Approaching to Join Replimune Group, Inc. (REPL) Class ActionContact Levi & Korsinsky - ACCESS Newswire
Class Action Filed Against Replimune Group, Inc. (REPL)September 22, 2025 Deadline to JoinContact The Gross Law Firm - PR Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is September 22nd - Morningstar
Zurcher Kantonalbank Zurich Cantonalbank Boosts Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Investors in Replimune Group, Inc. (REPL): Protect Your RightsContact Levi & Korsinsky Before September 22, 2025 - ACCESS Newswire
Replimune Group, Inc. (REPL) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of September 22, 2025 Deadline - ACCESS Newswire
Key resistance and support levels for Replimune Group Inc.Downside Risk Evaluation and Stock Analysis - Newser
Visualizing Replimune Group Inc. stock with heatmapsEntry Timing with Downside Risk Analysis - Newser
Securities Lawsuit Alert: Replimune Group, Inc. (REPL) InvestorsContact Levi & Korsinsky Before September 22, 2025 - ACCESS Newswire
Shareholders of Replimune Group, Inc. Should Contact Levi & - GlobeNewswire
Levi & Korsinsky Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025REPL - PR Newswire
Replimune Group Reports Increased Losses Amid Rising R&D Costs - TipRanks
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - Stockhouse
ROSEN, THE FIRST FILING FIRM, Encourages Replimune Group, - GlobeNewswire
Replimune Group Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Replimune Group (REPL) Reports Wider-than-Expected Quarterly Los - GuruFocus
Replimune Group: The Prospects For FDA Approval After Rejection (REPL) - Seeking Alpha
Shareholders that lost money on Replimune Group, Inc.(REPL) should contact The Gross Law Firm about pending Class ActionREPL - Barchart.com
Replimune Reports Fiscal First Quarter 2026 Financial Results an - GuruFocus
Biotech Replimune's Q1 net loss widens, cash balance drops - MarketScreener
Replimune Group, Inc. SEC 10-Q Report - TradingView
Replimune's Melanoma Drug Hits FDA Roadblock: Q1 Losses Widen to $86.7M as Clinical Trials Advance - Stock Titan
0.41%
0.88%
자본화:
|
볼륨(24시간):